A Phase 1-2 Study of TNG456 in People With Advanced Glioblastoma

Full Title

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination with Abemaciclib in Patients with Solid Tumors with MTAP Loss

Purpose

Researchers want to find the best dose of TNG456 to use alone or with abemaciclib to treat brain cancer. The people in this study have glioblastoma that has spread. In addition, their cancer is missing a protein called MTAP.

TNG456 is designed to target and kill cancer cells that do not make MTAP. If you join this study, you will get TNG456 alone or with abemaciclib. Both drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have glioblastoma that has grown after radiation therapy and at least one chemotherapy.
• Have recovered from the serious side effects of prior anti-cancer treatments before taking the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Lauren Schaff’s office at 212-610-0485.